Slotkin. ␤-Adrenergic modulation of muscarinic cholinergic receptor expression and function in developing heart. Am J Physiol Regulatory Integrative Comp Physiol 282: R1356-R1363, 2002. First published January 17, 2002 10.1152/ajpregu.00598.2001.-Imbalances of ␤-adrenoceptor (␤-AR) and muscarinic ACh receptor (mAChR) input are thought to underlie perinatal cardiovascular abnormalities in conditions such as sudden infant death syndrome. Administration of isoproterenol, a ␤ 1/␤2-AR agonist, to neonatal rats on postnatal days (PN) 2-5 caused downregulation of cardiac m 2AChRs and a corresponding decrement in their control of adenylyl cyclase activity. Terbutaline, a ␤ 2-selective agonist that crosses the placenta and the blood-brain barrier, was also effective when given either on PN 2-5 or during gestational days 17-20. Terbutaline failed to downregulate brain m 2AChRs, even though it downregulated ␤-ARs; ␤-ARs and m 2AChRs are located on different cell populations in the brain, but they are on the same cells in the heart. Destruction of catecholaminergic neurons with neonatal 6-hydroxydopamine upregulated cardiac but not brain m 2AChRs. These results suggest that perinatal ␤-AR stimulation shifts cardiac receptor production away from the generation of m 2AChRs so that the development of sympathetic innervation acts as a negative modulator of cholinergic function. Accordingly, tocolytic therapy with ␤-AR agonists may compromise the perinatal balance of adrenergic and cholinergic inputs. adenylyl cyclase; ␤-adrenergic receptor; adenosine 3Ј,5Ј-cyclic monophosphate; heart development; preterm delivery; tocolysis IN THE MATURE NERVOUS system, transsynaptic signals play a major role in the regulation of postsynaptic receptors and their associated signaling cascades (14, 30, 39, 61) . Typically for many neurotransmitters, increased presynaptic activity elicits uncoupling of postsynaptic receptors from their response elements (desensitization) (14, 39), and with continued stimulation, cell membrane receptors are removed from the surface and internalized (downregulation) (30, 61). Conversely, reductions in presynaptic activity are accompanied by supersensitivity and receptor upregulation (14, 30, 39, 61) . However, in the developing organism, a number of studies suggest that these relationships are absent or even reversed (8, 12, 13, 16, 59 ). For cardiac ␤-adrenoceptors (␤-ARs), repeated neonatal stimulation with the receptor agonist isoproterenol fails to elicit desensitization, and instead, signaling elements downstream from the receptor are induced, resulting in agonist-induced sensitization instead of the expected desensitization (13). Similarly, denervation at birth fails to elicit the expected ␤-AR supersensitivity (59). Indeed, in many systems, removal of transsynaptic input during development permanently obtunds the subsequent receptor-mediated responses (8, 12, 16) ; as these effects are often elicited before the formation of the majority of synaptic connections, the first few "pioneer" synapses may be of key importance in programming the subsequent development of receptor expression and function.
IN THE MATURE NERVOUS system, transsynaptic signals play a major role in the regulation of postsynaptic receptors and their associated signaling cascades (14, 30, 39, 61) . Typically for many neurotransmitters, increased presynaptic activity elicits uncoupling of postsynaptic receptors from their response elements (desensitization) (14, 39) , and with continued stimulation, cell membrane receptors are removed from the surface and internalized (downregulation) (30, 61) . Conversely, reductions in presynaptic activity are accompanied by supersensitivity and receptor upregulation (14, 30, 39, 61) . However, in the developing organism, a number of studies suggest that these relationships are absent or even reversed (8, 12, 13, 16, 59) . For cardiac ␤-adrenoceptors (␤-ARs), repeated neonatal stimulation with the receptor agonist isoproterenol fails to elicit desensitization, and instead, signaling elements downstream from the receptor are induced, resulting in agonist-induced sensitization instead of the expected desensitization (13) . Similarly, denervation at birth fails to elicit the expected ␤-AR supersensitivity (59) . Indeed, in many systems, removal of transsynaptic input during development permanently obtunds the subsequent receptor-mediated responses (8, 12, 16) ; as these effects are often elicited before the formation of the majority of synaptic connections, the first few "pioneer" synapses may be of key importance in programming the subsequent development of receptor expression and function.
In the developing heart, ␤-AR input appears to be important in establishing the competence of a variety of nonadrenergic, heterologous signals that operate through adenylyl cyclase (AC), by influencing the expression and function of signaling proteins other than the ␤-AR itself (13, 15, 16, (66) (67) (68) . The current study addresses receptor "cross talk" in myocardial cells, by assessing whether ␤-AR activity regulates the ontogeny of m 2 ACh receptors (m 2 AChRs), receptors whose actions directly oppose those of the ␤-ARs. The ontogenetic profiles of both the receptors themselves and their neuronal inputs are well established. ␤-ARs emerge earlier in embryonic life than do mAChRs (41) and regulate fetal heart function initially (7) through circulating catecholamines (25) or intrinsic cardiac adrenergic cells (17) . However, in terms of neuronal input, vagal cholinergic function appears first, in the early neonatal period, followed by the onset of sympathetic function during the second to third postnatal week (32, 53) . To delineate the role played by ␤-AR stimulation, we reversed the normal postnatal sequence by administering isoproterenol to neonates; in addition, we evaluated the effects of neonatal treatment with 6-hydroxydopamine (6-OHDA), which destroys catecholaminergic projections and thus maintains cholinergic dominance (13, 59) . By using terbutaline, a ␤-AR agonist that penetrates the placenta and the blood-brain barrier, we determined the potential for cross talk between ␤-ARs and m 2 AChRs, and we compared effects on cardiac receptors with those in the brain. Whereas cardiac ␤-ARs and m 2 AChRs are colocalized on myocytes, the receptors are present on disparate cell populations within the fetal brain (21, 43, 45, 52) . Presumably, control of the expression and/or function of m 2 AChRs by ␤-ARs would be likely to require cross talk within the same cell. Finally, in light of the widespread use of ␤-AR agonists to arrest preterm labor, this study provides an animal model of ␤-AR/m 2 AChR cross talk to evaluate the potential for tocolytics to disrupt cardiac autonomic function.
METHODS
Animal treatments. All studies were carried out in accordance with the declaration of Helsinki and with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health. Timed pregnant Sprague-Dawley rats were shipped by a climatecontrolled truck (transit time 12 h) and housed with free access to food and water. For studies of the effects of postnatal ␤-AR stimulation, pups were randomized at birth and redistributed to the nursing dams with a litter size of 10. Additionally, dams were reassigned randomly to different litters each day so as to distribute any dam-related differences equally among all litters. Within each litter, equal numbers of animals were assigned to the different treatment groups in a sex-matched design using approximately equal proportions of males and females. Beginning on postnatal day (PN) 2, animals were given a 4-day regimen of once-daily subcutaneous injections of either 1.25 mg/kg of L-isoproterenol HCl, 10 mg/kg of terbutaline hemisulfate, or an equivalent volume (1 ml/kg) of vehicle, consisting of 0.9% saline plus 0.1% ascorbic acid. These treatments have been shown to elicit maximal cardiac ␤-receptor stimulation in the neonate (1, 2, 13, 50) . Twenty-four hours after the last injection, animals were killed, hearts and brains were dissected, and the brain stem was isolated from the rest of the brain by removing the cerebellum and performing a cut rostral to the thalamus. All tissues were frozen with liquid nitrogen and stored at Ϫ45°C; preliminary studies verified that freezing and storage did not change any of the measured variables. In keeping with the vast literature on neonatal rat development, the cross fostering required for randomization did not affect nursing behavior nor did the dams reject or cannibalize any of the pups. Growth rates and receptor expression in the control group were within normative limits for unmanipulated animals (36, 54, 56, 58) . We also performed preliminary experiments comparing unmanipulated animals to cross-fostered controls and found no differences in receptor expression (data not shown).
The brain stem was studied because abnormalities of ␤-AR/mAChR balance in that region are thought to underlie cardiac and respiratory anomalies that increase the risk of perinatal mortality, including sudden infant death syndrome (SIDS) (11, 20, 54) . The brain stem undergoes its peak of neurogenesis prenatally (44) , so that synapses are forming in the early neonatal period, the time most likely for detection of effects of neurotransmitter cross talk on receptor expression.
For studies of prenatal terbutaline treatment, dams were given daily subcutaneous injections of 10 mg/kg of terbutaline hemisulfate or an equivalent volume (1 ml/kg) of vehicle on gestational days (GD) 17-20. This terbutaline regimen has been shown to elicit robust ␤-AR stimulation in the fetus, simulating the effects seen with its use as a tocolytic, including cardiac activation and enhancement of fetal lung surfactant synthesis (23, 24, 35) . Twenty-four hours after the third or fourth injection, dams were decapitated and fetal hearts and brains were removed. The fetuses or neonates from each dam were considered to be a single measurement, so that the number of determinations is the number of dams or litters.
The pharmacokinetics of terbutaline are undoubtedly different in the maternal-fetal unit compared with the neonate. However, we found equivalent ␤-AR downregulation in the fetal and neonatal liver after these terbutaline regimens (1, 2) . Given that the liver expresses predominantly the ␤ 2-AR subtype (10, 56) , the fact that terbutaline, a ␤2-selective agonist, displays equivalent efficacy toward hepatic ␤ 2-AR downregulation indicates that the treatment regimens are pharmacodynamically equivalent, despite any underlying pharmacokinetic differences.
In another set of experiments to delineate the role of innervation in the ontogeny of m 2AChRs, neonatal rats were sympathectomized at 1 day of age by administration of 6-OHDA HBr (150 mg/kg sc in saline-ascorbic acid vehicle), whereas controls received vehicle (1 ml/kg). This treatment causes a nearly complete and permanent destruction of peripheral catecholaminergic neurons (57) .
Receptor binding. Receptor binding capabilities were assessed by methods described in earlier publications (31, 65) . The overall strategy was to examine binding at a single subsaturating ligand concentration in preparations from every animal. The selection of a single concentration of radioligand for the receptor analysis enables the detection of changes in either Kd or Bmax but does not permit distinction between the two possible mechanisms. Accordingly, we used additional membrane preparations pooled from several animals in each treatment group for Scatchard analysis to identify which of the binding parameters was affected. This strategy was necessitated by the requirement to measure binding of two different ligands as well as six different measures of AC activity for each of the hundreds of membrane preparations involved in the study.
Tissues were thawed and homogenized (Polytron, Brinkmann Instruments, Westbury, NY; speed setting 4) in 39 volumes of ice-cold buffer containing 145 mM NaCl, 2 mM MgCl2, and 20 mM Tris (pH 7.5). When necessary, homogenates were strained through several layers of cheesecloth to remove connective tissue. For m2AChR binding, the homogenate was diluted with an equal volume of 10 mM sodiumpotassium phosphate buffer (pH 7.4) and sedimented at 40,000 g for 10 min. The resultant pellet was resuspended in phosphate buffer, and aliquots containing Ϸ320 g of membrane protein (28) were used for the ligand binding assays. Incubations in phosphate buffer contained a final concentration of 1 nM [
3 H]AFDX384, with or without 1 M atropine to displace specific binding. Incubations lasted 60 min at room temperature after which membranes were trapped on filter papers that had been presoaked with 0.1% polyethyleneimine. Nonspecific binding was ϳ10% of total binding. For Scatchard determinations, the concentration of AFDX384 was varied from 0.4 to 8 nM, with nonspecific binding ranging from 6 to 20% depending on the ligand concentration.
For ␤-AR binding determinations, the original tissue homogenate was sedimented at 40,000 g for 15 min wherein the pellets were washed twice, resuspended (Polytron) in homogenization buffer, resedimented, and then dispersed with a homogenizer (smooth glass fitted with a Teflon pestle) in 250 mM sucrose, 2 mM MgCl2, and 50 mM Tris (pH 7.5). [
125 I]iodopindolol (final concentration of 67 pM) was incubated with Ϸ125 g of membrane protein in a medium of 145 mM NaCl, 2 mM MgCl 2, 1 mM Na ascorbate, and 20 mM Tris (pH 7.5), for 20 min at room temperature in a total volume of 250 l. Nonspecific binding (displacement by 100 M isoproterenol) was generally ϳ10% of total binding.
AC activity. Membrane fractions were prepared as already described for ␤-AR binding. The membrane preparations were diluted 20-fold with 250 mM sucrose, 1 mM EGTA, and 10 mM Tris (pH 7.4) before the assay. Aliquots of cardiac membrane preparation containing 30 g of protein were incubated for 30 min at 30°C with final concentrations of 100 mM Tris ⅐ HCl (pH 7.4), 10 mM theophylline, 1 mM adenosine 5Ј-triphosphate, 10 mM MgCl 2, 1 mg bovine serum albumin, and a creatine phosphokinase-ATP-regenerating system consisting of 10 mM sodium phosphocreatine and 8 IU phosphocreatine kinase, in a total volume of 250 l. The enzymatic reaction was stopped by placing the samples in a 90-100°C water bath for 5 min, followed by sedimentation at 3,000 g for 15 min, and the supernatant solution was assayed for cAMP using radioimmunoassay kits. Preliminary experiments showed that the enzymatic reaction was linear well beyond the assay time period and was linear with membrane protein concentration; concentrations of cofactors were optimal.
The inhibitory effects of muscarinic agonists on AC were examined by comparing activities in the presence or absence of a maximally effective concentration (100 M) of carbachol or oxotremorine (6, 54) . Preliminary studies showed equivalent effects of the two agonists, although those obtained with oxotremorine were more consistent; results for the two stimulants were combined for presentation. Effects of the cholinergic agents were evaluated under three different conditions. First, we assessed the effects on basal AC activity. Second, we determined effects on activity in the presence of a ␤-AR stimulant, isoproterenol (100 M). Third, we evaluated effects on activity in the presence of forskolin (100 M), which acts directly on AC itself (49) . The concentrations of all the agents used here have been found previously to be optimal for effects on AC (6, 54) .
Data analysis. Data are presented as means Ϯ SE. For convenience, some data are presented as the percent change from control values. However, statistical tests were performed on the original data. Effects of ␤-AR agonist treatment were evaluated by multivariate ANOVA incorporating all relevant variables (treatment, age, tissue, receptor subtype, and in vitro conditions for the AC determinations), and with data log transformed whenever variance was heterogeneous. Where appropriate, interaction terms were obtained for treatment ϫ other variables, and individual differences between treatment groups were then established using Fisher's protected least significant difference. However, where there was only a main treatment effect in a multivariate design, only main effects were reported. Because there were no effects of any of the treatments on the concentration of membrane proteins (data not shown), results were the same regardless of whether receptor binding or AC activity was expressed per unit tissue weight or per milligram of membrane protein, and we restricted presentation to the latter parameter. Significance for main treatment effects was assumed at P Ͻ 0.05. However, for interactions at P Ͻ 0.1, we also examined whether lower-order main effects were detectable after subdivision of the interactive variables (60) .
Scatchard plots were fitted by linear regression analysis and compared across treatments using ANCOVA.
Materials. Animals were purchased from Zivic Laboratories (Pittsburgh, PA 
RESULTS

Administration of isoproterenol
To determine whether the decrement in receptor binding elicited a comparable reduction in cell signaling capabilities, we evaluated the ability of m 2 AChR agonists to inhibit AC activity (Fig. 2) . In control rats, addition of carbachol or oxotremorine to cardiac membrane preparations produced significant decrements in AC activity (main effect of agonist P Ͻ 0.0001), indicating effective linkage of the receptors to AC via the inhibitory G protein (G i ). The effect of muscarinic agonists was greatest in the presence of stimulation by forskolin (interaction of m 2 AChR agonist ϫ stimulant P Ͻ 0.0001). In vivo treatment of neonatal rats with isoproterenol on PN 2-5 produced a significant reduction of the effectiveness of m 2 AChR agonists by about the same proportion (15-20%) as the decline seen for receptor binding. We next determined if the period for ␤-AR regulation of m 2 AChR expression and function extends back into fetal stages. To ensure penetration of the ␤-AR agonist to the fetus, we used terbutaline, which is known to cross the placenta (4, 18, 33) . In addition to assessing m 2 AChR binding, we assessed ␤-AR downregulation so as to verify that fetal tissues were exposed to terbutaline levels sufficient to alter expression of its primary receptor target (1). After 4 days of terbutaline treatment on GD 17-20, fetal cardiac m 2 AChR and ␤-AR binding sites were downregulated to a small but significant degree, with approximately the same effect seen for the two receptor types (Fig. 3) . Terbutaline also penetrates into the brain (33), so we next compared the effects across the two tissues. Fetal terbutaline treatment failed to affect m 2 AChR expression in the brain, despite the fact that it elicited much greater ␤-AR downregulation than was seen in the heart. We also determined whether comparable effects could be elicited by postnatal terbutaline administration, given on the same schedule as in the isoproterenol studies (treatment on PN 2-5 and measurements on PN 6). Postnatal terbutaline treatment produced the same small (10%) decrement in cardiac m 2 AChRs that had been seen with fetal treatment: control 177 Ϯ 3 fmol/mg protein (n ϭ 16); terbutaline 160 Ϯ 4 fmol/mg (n ϭ 16), P Ͻ 0.002 vs. control.
We next determined if the small degree of fetal cardiac m 2 AChR downregulation seen after fetal terbutaline treatment was paralleled by a decrease in the ability of the receptors to inhibit AC activity (Fig. 4) . Although m 2 AChR agonists caused significant inhibition of AC on GD 20 (P Ͻ 0.0001), the effect was much larger by GD 21 (main effect of age P Ͻ 0.0001); terbutaline treatment had no significant effect on this pattern.
Finally, we determined whether tonic sympathetic activity played a role in the establishment of m 2 AChR expression. Newborn rats (PN 1) were given 6-OHDA to destroy the developing sympathetic nerve terminals so as to interrupt endogenous catecholaminergic input (57) . Three days later, we observed a significant in- values, which were: heart m2AChR 257 Ϯ 6 fmol/mg protein; heart ␤-AR 12.5 Ϯ 0.2; brain m2AChR 136 Ϯ 2; and brain ␤-AR 9.5 Ϯ 0.7. ANOVA across both receptor subtypes and both tissues appears at the top, with subdivision by tissue at the bottom. In the heart, the significant treatment difference was not distinguishable between the 2 receptor types (no interaction of treatment ϫ subtype), so only the main effect is reported without testing of individual subtypes. In the brain, the differences were subtype selective (interaction of treatment ϫ subtype), and the * denotes the selective treatment difference for ␤-AR binding. Fig. 4 . AC response to m2AChR stimulation in membrane preparations from control rats and rats that received terbutaline on GD 17-20. Data represent means Ϯ SE obtained from the number of animals shown in parentheses, evaluated as the percent change in isoproterenol-stimulated AC activity elicited by a maximally effective concentration (100 M) of carbachol or oxotremorine. ANOVA across both ages appears at the top; separate tests for each age were not conducted because of the absence of an effect of treatment or interaction of treatment ϫ age. Activities (pmol ⅐ min Ϫ1 ⅐ mg protein crease in cardiac m 2 AChRs of nearly 25%: control 238 Ϯ 6 fmol/mg protein (n ϭ 13); 6-OHDA 294 Ϯ 19 fmol/mg (n ϭ 13), P Ͻ 0.01 vs. control. The effect on m 2 AChRs was bigger than the effect on ␤-ARs, which actually showed a small (5%) nonsignificant decrease: control 9.3 Ϯ 0.8 fmol/mg protein (n ϭ 6); 6-OHDA 8.8 Ϯ 0.6 fmol/mg (n ϭ 6). The effect on m 2 AChRs was statistically distinguishable from the lack of effect on ␤-ARs (treatment ϫ subtype interaction P Ͻ 0.05). The promotional effect of 6-OHDA on m 2 AChRs persisted through the period over which sympathetic innervation normally develops [first 3 wk postnatally (53) ] but at a lower magnitude than that seen in the immediate neonatal period, with a 6% increase on PN 7 and a 15% increase on PN 17 (data not shown). Although these smaller effects were not in themselves statistically significant, they were also not distinguishable from the larger effect obtained on PN 4 (P Ͻ 0.05 for the main effect of 6-OHDA, but no significant interaction for 6-OHDA ϫ age), so the actual degree of persistence would need to be verified in future work. We also contrasted the effects of neonatal 6-OHDA treatment on cardiac m 2 AChR expression with results obtained in the brain stem. 6-OHDA penetrates the neonatal blood-brain barrier to elicit massive norepinephrine depletion (64) . Nevertheless, we did not observe upregulation of m 2 AChRs in the brain on PN 4, the point at which peak effects were seen in the heart: control 212 Ϯ 3 fmol/mg protein (n ϭ 4); 6-OHDA 208 Ϯ 13 fmol/mg (n ϭ 6). The lack of effect in the brain stem was distinguishable from the upregulation seen in the heart (significant 6-OHDA ϫ tissue interaction).
DISCUSSION
Results obtained in this study indicate that fetal or neonatal ␤-AR stimulation modulates the concentration and function of m 2 AChRs in the developing heart. Repeated administration of isoproterenol elicited up to a 25% decrease in the number of m 2 AChRs, an effect that was paralleled by a loss of the ability of m 2 AChR stimulation to inhibit AC activity. In addition, isoproterenol administration also shifted the affinity of m 2 AChRs, as evidenced by a decreased K d . Ordinarily, ligand binding affinity for m 2 AChRs tends to decrease with development, i.e., the K d increases with age (22) , so that our findings suggest that, in addition to altering the number and function of m 2 AChRs, excess ␤-AR stimulation promotes the maintenance of the immature conformation. It is unlikely that the alterations in binding affinity represent a difference in primary sequence of the receptor protein and, indeed, similar increases in K d are seen for cardiac ␤-ARs during neonatal development (27) . Taken together, these results suggest that the alterations in K d reside in factors that are common to multiple types of receptors, such as the membrane lipid milieu in which the receptors are embedded. Both age and ␤-AR stimulation are known to alter membrane lipids, leading to changes in receptor affinities (3), and ␤-AR stimulation has a profound effect on fetal/neonatal lipid metabolism (25) . Repetitive or excessive stimulation by exogenous ␤-AR agonists would thus be expected to influence the composition of cell membranes and hence the properties of membrane-associated receptors.
Our findings indicate that the reduction in m 2 AChRs elicited by ␤-AR stimulation likely represents specific, developmentally specified cross talk between the two receptor types. First, no such modulation of m 2 AChR levels is seen with ␤-AR agonist treatment in adults (29) . Second, the reduction in m 2 AChRs elicited by isoproterenol administration to neonates was observed, despite the fact that there was no downregulation of ␤-ARs; the inability of isoproterenol to elicit homologous receptor downregulation in neonatal heart agrees with our earlier findings (59) . Third, the downregulation was specific to the heart, where the ␤-ARs and m 2 AChRs are on the same cells, whereas no such effect was seen in the brain, where the two receptors reside on different cell populations (21, 43, 45, 52) . Fourth, our results indicated receptor-subtype selectivity, which will be discussed below. Although our results do not address the cellular mechanisms for ␤-AR/ m 2 AChR cross talk, these are likely to require additional interactions between cardiac cells and their systemic environment. Earlier work with cultured neonatal myocytes indicates that ␤-AR stimulation evokes only a transient decrease in m 2 AChR expression, followed by more prolonged increases in m 2 AChRs (34). However, culturing of myocytes alters their differentiation state and specifically affects the expression and function of G protein-coupled receptors (19, 63) . Given the prominent role played by endocrine factors in the expression and development of ␤-ARs and mAChRs as identified in earlier work from our and other laboratories (5, 26, 27, 38, 40, 42, 48, 55, 62) , maintenance of the in vivo hormonal milieu may provide key elements necessary to ␤-AR/m 2 AChR cross talk.
The ability of ␤-AR stimulation to reduce cardiac m 2 AChRs was also demonstrable in the fetus, indicating that the period for receptor cross talk extends to earlier stages of development. The effects of terbutaline, a ␤ 2 -selective agonist, on fetal m 2 AChRs were smaller than those seen after postnatal administration of isoproterenol, but they were indistinguishable from the effect of terbutaline administered postnatally. It is unlikely that the smaller fetal effect represents failure of terbutaline to penetrate the placenta: we found significant downregulation of ␤-ARs in both heart and brain, and our earlier work confirmed equivalent downregulation of hepatic ␤ 2 -ARs in the fetus and neonate after these terbutaline regimens (1, 2) . Instead, the current results point to preferential effects for the ␤ 1 -AR subtype. Terbutaline elicited a smaller downregulation of cardiac m 2 AChRs than did isoproterenol, a mixed ␤ 1 /␤ 2 -agonist, despite the fact that terbutaline, but not isoproterenol, evoked significant ␤-AR downregulation. The fetal heart has a higher proportion of ␤ 2 -ARs than does the neonatal or adult heart (1), so that, if this subtype were highly effective in modulating m 2 AChR expression, terbutaline would be more effective, not less effective, in the fetus than in the neonate. That does not mean that ␤ 2 -ARs are totally devoid of activity toward m 2 AChRs. Indeed, cross talk via the ␤ 2 -AR is likely to be more important in tissues in which this is the predominant subtype, such as the developing lung, where ␤-AR stimulation has been shown to elicit a robust decrease in m 2 AChRs (46). However, as those studies were performed in cell cultures, it remains to be demonstrated whether prevailing ␤ 2 -AR/m 2 AChR cross talk can be elicited to the same extent in vivo.
Although both neonatal isoproterenol and fetal terbutaline administration evoked a decrease in the number of cardiac m 2 AChRs, only the postnatal treatment elicited a significant decrement in the AC response to receptor stimulation. The linkage of m 2 AChRs to AC undergoes rapid development during the fetal treatment period, evidenced by the dramatic increase in muscarinic agonist effect between GD 20 and GD 21. Accordingly, there may be a significant proportion of spare (i.e., uncoupled) receptors at this time, so that the small decline elicited by terbutaline may be relatively less important. Alternatively, m 2 AChR downregulation may be offset by the much higher rate of protein synthesis in the fetus; the heart grows fivefold between GD 17 and GD 21, so most of the receptors and downstream signaling proteins are formed after the initiation of treatment. As yet a third alternative, the smaller degree of downregulation of m 2 AChRs seen with fetal terbutaline treatment (Ͻ10% decrease) may simply be too small to enable detection of an impact on cell signaling with the optimal conditions under which AC is measured in vitro. Studies of m 2 AChR function in vivo may be required to reveal the physiological significance of the loss of fetal m 2 AChRs.
The results obtained with isoproterenol or terbutaline treatment illustrate the effects of ␤-AR overstimulation on m 2 AChRs and their linked cellular responses. However, they do not address the issue of whether m 2 AChR expression is under tonic control by the development of adrenergic input. Accordingly, we performed additional studies in which sympathetic nerves were destroyed at birth by the administration of 6-OHDA. Neonatal sympathectomy elicited significant increases in cardiac m 2 AChRs of about the same magnitude seen for the decreases in receptors elicited by ␤-AR agonists. Indeed, the effect of 6-OHDA on m 2 AChRs was actually bigger than that on ␤-ARs, which showed no induction at the same age; failure of 6-OHDA to change ␤-AR expression in the neonate has been reported (59) . As with ␤-AR agonist treatment, there was no cross talk in the brain, again emphasizing that cross talk requires that the ␤-ARs and m 2 AChRs be located on the same cell. The promotional effect of 6-OHDA on cardiac m 2 AChRs persisted through the stage in which sympathetic innervation shows its most dramatic increases (53) , but perhaps surprisingly, at a lower magnitude of effect. This suggests that tonic adrenergic input does play a role in the programming of m 2 AChR development, but primarily in early stages, before the onset of reflex control of sympathetic activity. Thus only a few "pioneer" synapses may be required for receptor cross talk. The subsequent decline in the effect of denervation is likely to represent increasing contributions of nonneuronal factors to receptor expression [e.g., hormones (53) ]. Ultimately, then, the role of sympathetic neurons to the control of cardiac m 2 AChRs is a modulatory one, rather than representing an essential input.
␤-AR agonists are widely used as tocolytics in preterm labor, with treatment often extending for 10-20% of the total gestational period (9, 47) , just as used in the current study. Accordingly, it is essential to establish whether the current findings are likely to have corresponding functional effects on fetal/neonatal cardiac function. Although vagal control of heart rate and contractility are demonstrable at birth, parasympathetic input is relatively weak (32, 51) , so that even a minor effect on mAChRs may have an adverse functional effect. Indeed, imbalances of muscarinic/adrenergic receptor expression in the heart and in brain stem areas involved in cardiorespiratory regulation are implicated in perinatal morbidity and mortality, including SIDS (11, 20, 37, 54) . It is therefore notable that the changes seen here are comparable in magnitude to decreases in brain stem muscarinic receptor binding seen in infants that died of SIDS (20) or to shifts in brain stem and cardiac ␤-ARs and m 2 AChRs in animal models that recapitulate the cardiovascular changes thought to underlie perinatal hypoxia-induced brain damage (54) . Future work should concentrate on whether perinatal exposure to ␤-AR agonists compromises neonatal cardiac function, both under basal conditions and in situations like hypoxia that may trigger cardiovascular collapse.
